PharmAsia News

We've Moved

PharmAsia News has moved to a new enhanced Web platform.  For continued news and analysis related to Asia, please visit our new site at www.pharmasianews.com and sign up for a 30-day free trial.

Medivir Transfers HIV Drug Alovudine License To Beijing Mefuvir

SHANGHAI – Sweden-based Medivir AB will transfer its license and intellectual property for its HIV drug Alovudine (MIV-310) to subsidiary Beijing Mefuvir, Medivir announced Dec. 21.

MPI Research And Shanghai Medicilon Form Shanghai-Based Joint Venture

SHANGHAI – Michigan-based MPI Research has entered into a joint venture with Shanghai Medicilon to establish a preclinical research center in Shanghai that meets U.S. FDA and other international regulatory standards, the companies announced Dec 19.

Novelos Inks Deal With Hong Kong-Based Lee’s Pharma For Cancer, Hepatitis Compounds

SHANGHAI - Novelos Therapeutics signed an exclusive license agreement with Hong Kong-based Lee's Pharmaceutical Dec. 17, with an aim to expand the sales of its cancer and hepatitis compounds - NOV-002 and NOV205 - in the Greater China region.

Merck Recalls HIB Vaccines In China

SHANGHAI - Merck recalled more than 100,000 doses of its HIB vaccines exported to China, as part of its global initiative to recall certain lots of PedvaxHIB and Comvax vaccines due to sterilization concerns.

China Nepstar Signs 16 Cooperative Agreements With Multinational, Domestic Partners

SHANGHAI - China Nepstar Chain Drugstore signed strategic cooperative agreements with 16 pharmaceutical and health products suppliers as part of its store network expansion plan for 2008, the drugstore chain announced Dec. 14.

Chinese Device Maker Weigao Banks On Medtronic’s Brand Name For International Backbone

SHANGHAI - A new joint venture formed with Medtronic will give Chinese device maker Weigao the international presence it needs to bring the market to its orthopedic products.

Shanghai FDA Withdraws GMP Certificates, Suspends Production Of Drug Makers As Part Of “Five Links” Program

SHANGAHI - Shanghai FDA withdrew two GMP certificates and suspended the production of two companies in an effort to enhance compliance by drug and device manufacturers to the “five links” program, the Shanghai government announced Dec. 10.

China Shifts Drug Recall Burden To Manufacturers In Move To Increase Accountability

SHANGHAI - China’s State FDA launched a new nationwide drug recall system Dec. 10, with an aim to set up an effective cooperative system between the government and pharmaceutical companies, and encourage them to recall unsafe drugs voluntarily.

China’s SFDA Cancels Drug Maker’s License Following Investigation Of Tainted Products

SHANGHAI – China’s State FDA withdrew Shanghai Hualian Pharmaceutical's drug production license because the company’s two leukemia drugs were found to be contaminated and caused considerable damage to patients, the drug safety watchdog announced at a Dec. 12 press conference in Beijing.